This mutation enhances in vitro protein kinase activity ∼3-fold [6,7], indicating that abnormal increase in the kinase activity of LRRK2 is involved in the pathogenesis of Parkinson's disease, suggesting that LRRK2 kinase inhibitors have therapeutic benefit for the treatment of Parkinson's disease. The gene discussed is LRRK2; the disease is Parkinson disease.